H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

Core Insights - CG Oncology, Inc. (NASDAQ:CGON) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - H.C. Wainwright has raised the price target for CG Oncology to $80 from $75, maintaining a Buy rating, citing advancements in biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer [2] - The company reported FY25 EPS of ($2.08), which was below consensus estimates of ($0.58), but revenue of $4.04 million exceeded the consensus estimate of $515,180 [3] Company Developments - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutics for bladder cancer patients [4] - The Phase 3 PIVOT-006 trial in intermediate-risk NMIBC is highlighted as a key catalyst for 2026, which could expand the company's clinical and commercial opportunities [2] - Upcoming data from the CORE-008 Cohort CX trial evaluating cretostimogene in combination with gemcitabine is expected in the coming quarter [3]